NCT01431898 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection


Sponsors: Gilead Sciences	Phases: Phase I
Indications	Acronym:
Hepatitis C
Age Groups: Adult	Gender: Both
Names: Drug: GS-9669 tablets Drug: Placebo to Match GS-9669 tablet	Enrollment: 70

Additional information about NCT01431898.